Wall Street Zen Upgrades Grace Therapeutics to Hold Rating

Grace Therapeutics (NASDAQ: GRCE) received an upgrade to a “hold” rating from Wall Street Zen in a research report released on October 6, 2023. This comes as the company navigates a challenging financial landscape, having recently reported disappointing quarterly earnings.

In contrast, Weiss Ratings reiterated a “sell (d-)” rating on Grace Therapeutics just a few days earlier, on October 8. This mixed feedback highlights the varied perspectives among analysts regarding the stock’s potential. Currently, two analysts have assigned a Buy rating, while one has issued a Sell rating. According to data from MarketBeat.com, Grace Therapeutics holds an average rating of “Hold” with a price target of $12.00.

Latest Earnings Report

Grace Therapeutics announced its quarterly earnings results on November 13, 2023, revealing an earnings per share (EPS) of ($0.15). This figure fell short of analysts’ consensus estimates of ($0.12), marking a miss of $0.03. Analysts forecast that the company will report an EPS of ($1.06) for the current fiscal year, indicating ongoing financial challenges.

Institutional Investments in Grace Therapeutics

Several institutional investors and hedge funds have made recent adjustments to their holdings in Grace Therapeutics. Stratos Wealth Partners LTD. acquired a new position during the fourth quarter, investing approximately $39,000. Similarly, SeaCrest Wealth Management LLC bought in during the third quarter for about $42,000.

Additionally, Millington Financial Advisors LLC took a new position valued at $59,000 in the second quarter. Palumbo Wealth Management LLC also acquired a new stake in the same period, valued at $144,000. Notably, ADAR1 Capital Management LLC increased its position by 98.4% in the third quarter, now owning 350,450 shares worth approximately $1,043,000 after purchasing an additional 173,823 shares.

Currently, institutional investors and hedge funds own approximately 6.08% of Grace Therapeutics’ stock, reflecting a cautious interest amidst the company’s fluctuating performance.

Grace Therapeutics, Inc., based in the United States, is dedicated to discovering and developing innovative therapies for rare genetic diseases. Utilizing a proprietary platform that combines advanced molecular biology and biological engineering, the company focuses on gene-based and protein-based candidates aimed at addressing specific genetic drivers of disease. Its pipeline includes several preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.

As the company continues to navigate these challenges, the market will be watching closely for any signs of recovery or further decline in performance.